Business Description
Tenaya Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US87990A1060
Total Employee Number:
70Description
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.7 | |||||
3-Year EPS without NRI Growth Rate | 40.2 | |||||
3-Year FCF Growth Rate | 45.6 | |||||
3-Year Book Growth Rate | -46.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.55 | |||||
9-Day RSI | 38.97 | |||||
14-Day RSI | 44.96 | |||||
3-1 Month Momentum % | 6.16 | |||||
6-1 Month Momentum % | -0.59 | |||||
12-1 Month Momentum % | -16.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.75 | |||||
Quick Ratio | 5.75 | |||||
Cash Ratio | 4.82 | |||||
Days Sales Outstanding | 17239.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -48 | |||||
Shareholder Yield % | -30.36 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -38159.11 | |||||
Net Margin % | -36891.11 | |||||
EBITDA Margin % | -34808.89 | |||||
FCF Margin % | -28725.33 | |||||
OCF Margin % | -28616 | |||||
ROE % | -78.08 | |||||
ROA % | -63.55 | |||||
ROIC % | -163.41 | |||||
3-Year ROIIC % | -70.78 | |||||
ROC (Joel Greenblatt) % | -214.71 | |||||
ROCE % | -73.91 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 773.1 | |||||
PB Ratio | 1.58 | |||||
Price-to-Tangible-Book | 1.57 | |||||
EV-to-EBIT | -1.13 | |||||
EV-to-Forward-EBIT | -0.92 | |||||
EV-to-EBITDA | -1.24 | |||||
EV-to-Forward-EBITDA | -0.92 | |||||
EV-to-Revenue | 431.07 | |||||
EV-to-Forward-Revenue | 20.18 | |||||
EV-to-FCF | -1.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.49 | |||||
| Price-to-Net-Cash | 3.21 | |||||
Earnings Yield (Greenblatt) % | -88.5 | |||||
FCF Yield % | -38.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TNYA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tenaya Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.225 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 4.1696 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 109.32 | ||
| 14-Day RSI | 44.96 | ||
| 14-Day ATR ($) | 0.057059 | ||
| 20-Day SMA ($) | 0.811055 | ||
| 12-1 Month Momentum % | -16.42 | ||
| 52-Week Range ($) | 0.5316 - 2.35 | ||
| Shares Outstanding (Mil) | 217 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tenaya Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tenaya Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 13 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:10 | 0.79 (-8.63%) | ||
| General meeting for 2026 | 2026-05-27 08:00 | 0.78 (+1.56%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 0.75 (-5.48%) | ||
| Annual report for 2025 | 2026-03-11 | 0.90 (-6.77%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 0.90 (-6.77%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 13:00 | 0.89 (+13.85%) | ||
| RIDGEâ„¢-1 Phase 1b/2 clinical trial of TN-401 gene therapy | 2025-12-11 17:00 | 1.40 (-2.10%) | ||
| Guidance call for 2025 | 2025-11-10 08:00 | 1.28 (-2.29%) |
Show
Entries
Tenaya Therapeutics Inc Frequently Asked Questions
What is Tenaya Therapeutics Inc(TNYA)'s stock price today?
The current price of TNYA is $0.77. The 52 week high of TNYA is $2.35 and 52 week low is $0.53.
When is next earnings date of Tenaya Therapeutics Inc(TNYA)?
The next earnings date of Tenaya Therapeutics Inc(TNYA) is 2026-08-06 Est..
Does Tenaya Therapeutics Inc(TNYA) pay dividends? If so, how much?
Tenaya Therapeutics Inc(TNYA) does not pay dividend.
Guru Commentaries on NAS:TNYA
No articles.
Press Release
Articles on Tenaya Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers